New hope for pancreatic cancer patients: experimental immunotherapy offered outside clinical trial
Disease control
AVAILABLE
This program provides access to an experimental immunotherapy called ELI-002 7P for patients with a specific type of pancreatic cancer (with KRAS or NRAS mutations) who are at high risk of the cancer coming back after surgery. It is for patients who have no other good treatment o…
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC